...
首页> 外文期刊>Expert opinion on therapeutic targets >Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target.
【24h】

Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target.

机译:树突状细胞诱导致病性细胞毒性T淋巴细胞耐受性:一种新型治疗靶点。

获取原文
获取原文并翻译 | 示例
           

摘要

IMPORTANCE OF THE FIELD: Dendritic cells (DCs) have an important role, both direct and indirect, in controlling the expansion and function of T cells. Of the different subsets of T cells, cytotoxic T lymphocytes (CTLs/CD8(+) T cells) have been implicated in the pathogenesis and development of many diseases, including various forms of autoimmunity and transplant rejection. It may therefore be of therapeutic benefit to control the function of CTL in order to modulate disease processes and to ameliorate disease symptoms. Currently, pharmacological approaches have been employed to either directly or indirectly modulate the function of T cells. However, these treatment strategies have many limitations. Many experimental data have suggested that it is possible to alter CTL activity through manipulation of DC. AREAS COVERED IN THIS REVIEW: Novel strategies that condition DCs to influence disease outcome through manipulation of CTL activity, both directly and indirectly. This includes the modulation of co-stimulation, negative co-stimulation, as well as manipulation of the cytokine milieu during CTL generation. Furthermore, DCs may also impact CTL activity through effects on effector and regulatory cells, along with manipulation of bioenergetic regulation, apoptotic-cell mediated tolerance and through the generation of exosomes. The implications of related interventions in the clinical arena are in turn considered. WHAT THE READER WILL GAIN: Insight into such indirect methods of controlling CTL activity allows for an understanding of how disease-specific T cells may be regulated, while also sparing other aspects of adaptive immunity for normal physiological function. Such an approach towards the treatment of disease represents an innovative therapeutic target in the clinical arena. TAKE HOME MESSAGE: There are numerous innovative methods for using DCs to control CTL responses. Manipulation of this interaction is thus an attractive avenue for the treatment of disease, particularly those of immune dysregulation, such as seen in autoimmunity and transplantation. With the number of studies moving into clinical stages constantly increasing, further advances and successes in this area are inevitable.
机译:领域的重要性:树突状细胞(DC)在控制T细胞的扩增和功能中具有直接和间接的重要作用。在T细胞的不同亚群中,细胞毒性T淋巴细胞(CTLs / CD8(+)T细胞)与许多疾病的发病机理和发展有关,包括各种形式的自身免疫和移植排斥。因此,控制CTL的功能以调节疾病过程和改善疾病症状可能具有治疗益处。当前,已经采用药理学方法直接或间接调节T细胞的功能。但是,这些治疗策略有很多局限性。许多实验数据表明,通过控制DC可以改变CTL活性。本综述涵盖的领域:调节DC的新策略,可通过直接或间接地控制CTL活性来影响疾病结果。这包括共刺激的调节,负共刺激以及CTL生成过程中细胞因子环境的操纵。此外,DC也可能通过影响效应细胞和调节细胞,以及操纵生物能调节,凋亡细胞介导的耐受性以及通过外泌体的生成来影响CTL活性。反过来考虑相关干预措施在临床领域的意义。读者的收获:对控制CTL活性的这种间接方法的深入了解有助于理解疾病特异性T细胞的调控方式,同时也保留了正常生理功能的适应性免疫的其他方面。这种治疗疾病的方法代表了临床领域的创新治疗目标。温馨提示:有许多使用DC来控制CTL响应的创新方法。因此,这种相互作用的操纵是治疗疾病的诱人途径,尤其是免疫失调的疾病,例如在自身免疫和移植中所见。随着进入临床阶段的研究数量不断增加,在这一领域的进一步发展和成功是不可避免的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号